This study assess if it is possible to provide produce as a prescription in prenatal clinical care for pregnant women and to understand the impact that may have on their health and the health of their newborns after delivery.
Researchers at Tufts Medical Center are conducting a study on the benefits of mepivacaine in neuraxial anesthesia for certain neurosurgical procedures. The purpose of this study is to see if mepivacaine, a local anesthetic, can shorten your time in the recovery room/hospital; decrease the amount of time before you can walk after surgery; allow you to urinate sooner after surgery; and reduce any nausea and vomiting that you might experience after anesthesia and surgery.
Evaluate the correlation between ICU Skeletal muscle loss and protein intake and investigate the lack of daily protein intake by the presence of loss of rectus femoris muscle quantity and quality.
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
After completing enrollment in the original DEFENDO Study, patients will be invited to enter the DEFENDO Long-Term Follow-up Study (all standard of care is permitted). Two additional long-term follow-up visits will occur at 18- and 24-months to evaluate long-term clinical outcomes. No study treatment will be provided. Patients will be treated per standard of care as determined by the Investigator and will document topical ophthalmic medications currently being administered at time of study participation.
This research is being done to study a potential method of improving blood flow and oxygen delivery to the organs of patients on VA-ECMO. This study involves positioning the return cannula in the aorta, which is the main artery that carries blood away from the heart. We aim to prove that returning oxygenated blood to the aorta is safe and feasible. We also aim to better understand the effects that this method may have on the forces that affect blood flow and heart function.
The primary objective of this study is to assess the efficacy of rifaximin SSD-40IR versus placebo to delay the occurrence of HE-related hospitalization.
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL). Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R FL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab.
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).
This is a prospective, multi-center, single-arm, early feasibility study that aims to evaluate the safety of the Impella BTR™ in adult patients requiring left-ventricular hemodynamic support, and to evaluate the effectiveness of the Impella BTR™ in supporting patients to recovery or their next therapy.
The main objective of this study is to prospectively evaluate the effect of prophylactic intra-operative ventricular tachyarrhythmia ablation (VTA) at the time of left ventricular assist device (LVAD) implantation on post-implant total recurrent VTA events, after accounting for the competing risk of death, from discharge to an average follow-up of 18 months (with a minimum of 9 months) after LVAD implantation.
Patients who need vision testing (acuity and fields) will be asked to be tested at home or at the bedside with the ViuALL device. They and their phyysicians will be asked about the advantages and disadvantages of the new device.
Men with severe symptoms of bladder outlet obstruction often have associated bladder fibrosis leading to diminished bladder contractility. Planning to perform a pilot study using 10 urine samples from controls without urinary symptoms and from 10 men with severe urinary symptoms as noted on the International Prostate Symptom Score (IPSS) questionnaire. Assays will determine levels of collagen within the urine samples from both groups.
The study will evaluate the efficacy, safety and pharmacokinetics of faricimab compared with aflibercept in patients with macular edema due to branch retinal vein occlusion (BRVO) up to the primary endpoint at Week 24.
The aim of this study is to investigate the use of benralizumab in patients with eosinophilic CRSwNP, and comorbid asthma, whose severity is consistent with a need for surgery despite ongoing treatment with intranasal corticosteroids and a history of treatment with systemic corticosteroids or prior surgery for CRSwNP. The effect of benralizumab 30 mg on nasal polyps will be assessed on top of standard of care therapy with INCS over a 56-week treatment period.
This trial has two parts. Part A, an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab. Part B, the Randomized Phase of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy to generate pivotal efficacy and safety data in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Randomization will be stratified by PDL1 CPS <20 vs PD-L1 CPS ≥20, and prior chemotherapy (yes vs no).
Randomized Arm: This is a prospective, open label, randomized, controlled, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in patients enrolled with NYHA Class II Heart Failure. Single Arm:This is a prospective, open label, single arm, controlled, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System linked with a clinician-directed patient self-management strategy in patients enrolled with NYHA Class III Heart Failure comparedto a Performance Goal (PG).
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.
